期刊文献+

HPLC测定利奈唑胺注射液中利奈唑胺的含量及其有关物质 被引量:7

Determination of Linezolid Content and Related Substances in Linezolid Injection by HPLC
原文传递
导出
摘要 目的建立高效液相色谱法测定利奈唑胺注射液中利奈唑胺含量及其有关物质的方法。方法色谱柱为EclipseXDB-C18,流动相为甲醇-水(45∶55),流速1.0 mL.min 1,检测波长254 nm,柱温25℃。结果利奈唑胺浓度在0.5~250mg.L 1内线性关系良好(r=0.999 8),最低检测量1 ng,低、中、高3种浓度的平均回收率分别为99.3%,100.9%,100.5%。结论该方法简便、灵敏、准确,专属性强,适合于利奈唑胺注射液中利奈唑胺含量及其有关物质的测定。 OBJECTIVE To establish an HPLC method for the determination of linezolid and related substances in linezolid injection. METHODS The analytical column was Eclipse XDB-C18, the mobile phase was methanol-water(45 : 55), the flow rate was 1.0 mL·min-1. The detection wavelength was 254 nm, and the column temperature was 25℃. RESULTS The linear range of calibration curve was 0.5-250 mg·L-1(r=0.999 8), and the limit of detection was 1 ng. The average recovery of three concentrations were 99.3%, 100.9%, 100.5%, respectively. CONCLUSION The method is simple, sensitive andaccurate, and can control the quality of the preparation effectively.
出处 《中国现代应用药学》 CAS CSCD 2012年第7期655-657,共3页 Chinese Journal of Modern Applied Pharmacy
关键词 高效液相色谱法 利奈唑胺注射液 有关物质 HPLC linezolid injection related substances
  • 相关文献

参考文献5

  • 1ABENA P A, MATHIEUX V G, SCHEIFF J M, et al. Linezolid and reversible myelosuppression [J]. J Am Med Assoc, 2001, 286(16): 1973-1974.
  • 2TOUTAIN J, BOSELLI E, DJABAROUTI S, et al. Determination of linezolid in plasma and bronchoalveolar lavage by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method [J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2004, 813(1): 145-150.
  • 3BOAK L M, LI J, NATION R L, et al. High-performance liquid chromatographic method for simple and rapid determination of linezolid in human plasma [J]. Biomed Chromatogr, 2006, 20(8): 782-786.
  • 4LOVERING A M, LE F R, HOVSEPIAN L, et al. Pharma- cokinetic evaluation of linezolid in patients with major thermal injuries [J]. J Antimicrob Chemother, 2009, 63(3): 553-559.
  • 5董海燕,董亚琳,王雪,杨华,刘娟娟.HPLC法测定人血清中利奈唑胺浓度及其临床应用[J].药物分析杂志,2010,30(2):199-203. 被引量:22

二级参考文献27

  • 1Abena PA, Mathieux VG, Scheiff JM, et al. Linezolid and reversible myelosuppression. J Am Med Assoc ,2001,286 : 1973.
  • 2Santos RP, Prestidge CB, Brown ME, et al. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis. Pul- mortology,2009,44(2) : 148.
  • 3Lovering AM, Le FR, Hovsepian L, et al. Pharmacokinetic evaluation of linezolid in patients with major thermal injuries. J Antimicrob Chemother,2009,63 ( 3 ) :553.
  • 4Brier ME, Stalker D J, Aronoff GR, et al. Pharmaeokineties of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother, 2003,47 (9) :2775.
  • 5Tsuji Y, Hiraki Y, Mizoguchi A ,et al. Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure. J Infect Chemother, 2008,14 ( 2 ) : 156.
  • 6Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of staphylococcus aureus. Lancet ,2001,358:207.
  • 7Ruiz ME, Guerrero IC, Tuazon CU. Endocarditis caused by methicillin -resistant Staphylococcus aureus:treatment failure with linezolid. Clin Infect Dis ,2002,35:1018.
  • 8Gonzales RD, Schreckenberger PC, Graham MB,et al. Infections due to vancomycin - resistant enterococcus faecium resistant to linezolid. Lancet ,2001,357 : 1179.
  • 9Attassi K, Hershberger E, Alam R,et al. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis ,2002,34:695.
  • 10MacGowan AP. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother, 2001,48 ( Suppl SI ) : 17.

共引文献21

同被引文献33

引证文献7

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部